Seven Fleet Capital Management LP Has $510,000 Holdings in Compass Therapeutics, Inc. $CMPX

Seven Fleet Capital Management LP lowered its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 75.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 233,066 shares of the company’s stock after selling 707,472 shares during the period. Seven Fleet Capital Management LP’s holdings in Compass Therapeutics were worth $510,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the period. Parallel Advisors LLC acquired a new position in Compass Therapeutics in the first quarter valued at $28,000. Creative Planning bought a new stake in Compass Therapeutics during the second quarter valued at $30,000. State of Wyoming acquired a new stake in Compass Therapeutics during the 2nd quarter worth about $31,000. Finally, Strs Ohio acquired a new stake in Compass Therapeutics during the 1st quarter worth about $34,000. 68.43% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CMPX. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. LADENBURG THALM/SH SH started coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price for the company. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a report on Monday, June 1st. Piper Sandler increased their price target on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Wall Street Zen lowered shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $11.77.

Compass Therapeutics Price Performance

CMPX stock opened at $2.38 on Friday. The stock has a market capitalization of $428.61 million, a PE ratio of -5.95 and a beta of 0.95. The company’s 50-day moving average is $2.22 and its 200-day moving average is $3.32. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts anticipate that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.